General

Ventricular ectopy is a very common clinical problem. Nearly everyone has premature ventricular complexes (PVCs) at some point in life, but only some patients perceive them as symptomatic. New-onset ectopy, worsening of previous symptoms, or warning symptoms associated with ectopy often prompt medical evaluation.

​

In the assessment of a patient with PVCs, the most important question is whether there is underlying structural heart disease, ischemia, an inherited arrhythmia syndrome, or another treatable cause. If the heart is structurally normal and no high-risk features are present, PVCs are usually benign. For many patients, simply knowing that the condition is not dangerous provides substantial relief.

​

If structural heart disease is present, treatment is directed primarily at the underlying disease and only secondarily at the ectopy itself. In a structurally normal heart, drug therapy is needed only in some patients, and even then the main goal is usually symptom relief. Beta blockers are a safe first-line option, although efficacy is variable. In highly symptomatic patients or in the setting of a high PVC burden, catheter ablation can be an effective treatment.

​

A high burden of ventricular ectopy should almost always be investigated. In most cases, the cornerstones of evaluation are a careful history, physical examination, and 12-lead ECG. When needed, assessment is supplemented with ambulatory ECG monitoring, echocardiography, exercise testing, cardiac MRI, or selectively invasive studies.

 

Definition and Mechanisms

A PVC is a premature depolarization arising from the ventricles. Ventricular ectopy refers to isolated PVCs or at most two consecutive ventricular beats.

​

Ventricular tachycardia (VT) is defined as at least three consecutive ventricular beats, usually at a rate >100/min. If VT terminates spontaneously within 30 seconds, it is nonsustained VT (NSVT). VT lasting >30 seconds is defined as sustained VT. The term sustained VT is also used when the arrhythmia lasts <30 seconds but causes hemodynamic compromise, such as hypotension, reduced level of consciousness, chest pain, heart failure, or another circulatory disturbance requiring immediate treatment.

 

Ventricular arrhythmias can also be classified by morphology:

• Monomorphic / unifocal = uniform morphology, usually arising from the same focus

• Polymorphic / multifocal = varying morphology, with variable origin or a more unstable substrate

 

PVCs can arise through three main mechanisms: increased automaticity, triggered activity, and re-entry. In structural heart disease, re-entry is the most common mechanism because scar and fibrosis can slow conduction and permit an impulse to circulate back into tissue that has already recovered. In idiopathic ventricular arrhythmias, which are usually monomorphic, focal mechanisms are more common, especially triggered activity and abnormal automaticity, although some arrhythmias may also be related to micro-re-entry. Etiologically, ventricular arrhythmias can be grouped into those associated with structural heart disease, idiopathic arrhythmias, and arrhythmias associated with primary electrical heart disease. In electrical heart diseases there is no single dominant mechanism common to all conditions, but triggered activity is particularly important in long QT syndrome, where EAD-mediated arrhythmia susceptibility is central, and in CPVT, where DAD-mediated triggered activity is the typical mechanism.

​

Increased automaticity means that a ventricular or Purkinje cell begins to function as an additional pacemaker. The cell spontaneously depolarizes during diastole toward threshold and can generate a premature ventricular beat without an afterdepolarization caused by the preceding beat. In other words, the cell generates impulses independently.

Triggered activity means that a new impulse is triggered by the preceding action potential. In this mechanism, the new ventricular beat does not arise from intrinsic pacemaker function; rather, the preceding electrical event leaves behind an abnormal depolarization that may reach threshold. For this reason, both EADs and DADs belong to triggered activity rather than automaticity.

​

EAD (early afterdepolarization) occurs during repolarization, before the previous action potential has ended. It is usually associated with prolonged action potentials and QT prolongation, and it is especially favored by bradycardia and long pauses. In practice, repolarization is prolonged to the point that the cell begins to depolarize again before the previous electrical event has fully ended. A long cycle length can increase repolarization instability and predispose to the EAD phenomenon. At the cellular level, a long plateau/repolarization phase allows depolarizing ion currents—especially L-type calcium current and, in some situations, late sodium current—to reactivate or persist too long, generating a new abnormal depolarization before full repolarization. This creates a new inward depolarizing current. If this afterdepolarization reaches threshold, a new ventricular beat or arrhythmia may occur. Normally, during the cardiac myocyte action potential, L-type calcium channels open after depolarization and allow Ca²⁺ to enter the cell. This current helps maintain the phase 2 plateau, preventing the membrane potential from immediately returning to rest. At the same time, incoming Ca²⁺ initiates excitation-contraction coupling: it triggers further calcium release from the sarcoplasmic reticulum and thus myocardial contraction.

 

DAD (delayed afterdepolarization) occurs only after complete repolarization. It is usually related to intracellular calcium overload, which may be promoted by beta-adrenergic stimulation, tachycardia, or digitalis effect. In DAD, spontaneous calcium release from the sarcoplasmic reticulum activates a transient inward current and produces an afterdepolarization. If this reaches threshold, a new ventricular beat occurs. Spontaneous calcium release is primarily due to excess intracellular calcium and sarcoplasmic reticulum calcium overload. This mechanism is particularly favored by adrenergic activation, rapid heart rate, and digitalis effect.

​

In re-entry, the impulse does not arise from a new focus but continues to circulate in a local conduction loop within tissue where conduction is slowed and refractory periods vary. If the circuit is short and extinguishes quickly, the result may be only a single PVC. If the pathway remains open for several cycles, VT may result. Micro-re-entry refers to the same phenomenon occurring in a very small local circuit.

​

Clinically, it is also useful to understand why a slow sinus rate can in some situations predispose to PVCs. When normal sinus impulses arrive less frequently, their overdrive-suppressive effect weakens, and the long cycle length may also favor pause-dependent mechanisms, especially EADs. This is not a universal explanation for PVCs in all patients, however, because in some patients ectopy increases instead during exercise or sympathetic activation.

​

In simplified terms: in automaticity, the focus generates the impulse itself; in triggered activity, the previous beat triggers the next; and in re-entry, the same impulse circulates back. This framework is clinically useful because different mechanisms are associated with different underlying diseases, provoking factors, and, to some extent, different treatment responses.

 

Prevalence and Predisposing Factors

The tendency to develop PVCs is very common. In healthy individuals, PVCs are found in approximately 0.5–2.2% on a random 12-lead ECG, in about half during 24–48-hour monitoring, and in about 14–44% during clinical exercise testing. Prevalence increases with age and is higher in the presence of heart disease.

​

In a structurally normal heart, most ventricular arrhythmias arise from the outflow tract region. Of these, about 80–90% originate from the right ventricular outflow tract (RVOT), with the remainder arising from sites such as the left ventricular outflow tract (LVOT), septum, pulmonary artery, aortic sinus of Valsalva, conduction system region, or epicardium.

 

PVCs may be the first sign of early heart disease, such as coronary artery disease, valvular disease, heart failure, cardiomyopathy, or untreated hypertension.

​

Factors that predispose to PVCs include especially:

• aging

• intense physical exertion

• stress, sleep deprivation, exhaustion

• caffeine, tobacco, alcohol, and drugs

• sympathomimetics, xanthine derivatives, and digitalis toxicity

• hypokalemia

• thyroid dysfunction

• lung disease and hypoxia

• acute central nervous system disorders

• coronary artery disease, prior myocardial infarction, heart failure, cardiomyopathies, congenital heart disease, valvular disease, and inherited arrhythmia syndromes

 

Symptoms

Most PVCs are asymptomatic or only mildly symptomatic. In some patients, however, they are very bothersome and can significantly impair quality of life.

​

Typical symptoms include:

• thumping or “skipped” sensations in the chest

• extra or unusually forceful heartbeats

• a pause sensation or the feeling that a beat is missed

• a lump-in-the-throat sensation

• a brief stab or oppressive sensation in the chest

• reduced exercise capacity

• dizziness

 

More serious symptoms include:

• presyncope or syncope

• exertional chest pain, dyspnea, or weakness

• recurrent tachycardia episodes

• worsening heart failure or myocardial ischemia

 

If the patient has episodes of tachycardia, it should be determined whether these represent atrial fibrillation, supraventricular tachycardia, or ventricular tachycardia.

​

Prognosis and Risk Assessment

The prognostic significance of PVCs depends above all on whether the patient has structural heart disease. In a structurally normal heart, monomorphic PVCs with an idiopathic appearance are usually benign. In structural heart disease, PVCs—and especially NSVT episodes—may be a marker of an electrical substrate such as scar tissue and may be associated with an increased risk of ventricular arrhythmias and sudden cardiac death.

 

Risk assessment is not based on a single PVC-count threshold alone, but on the overall picture:

• left ventricular function and LVEF

• structural abnormalities on echocardiography or CMR

• scar or abnormal tissue, especially late gadolinium enhancement

• syncope or presyncope

• couplets, triplets, and NSVT

• polymorphic morphology

• exercise behavior

• family history

• possible suspicion of ischemia

 

After myocardial infarction, PVCs are common, but with contemporary management, reduction of sudden death risk is based primarily on optimal treatment of coronary artery disease and heart failure and, in selected patients, ICD therapy.

Consecutive ventricular beats (couplet, triplet, NSVT) mean that the arrhythmia is no longer merely a single isolated event but has a tendency to continue as a repetitive ventricular rhythm. This indicates greater arrhythmic complexity. A couplet shows that the ectopic focus or arrhythmic substrate can produce at least two consecutive ventricular beats; in other words, the arrhythmia is more “organized” and closer to a short VT run than to an isolated ectopic beat. In practice, this may suggest either a more irritable focus, a conduction substrate compatible with re-entry (eg, scar), or another structural/electrical abnormality that permits repetitive ventricular activity. Thus, “complex ventricular arrhythmias” function more as a warning sign of a more pathological substrate.

 

The EHRA/HRS/APHRS consensus states that an NSVT finding should in itself always trigger further evaluation. This does not mean that every NSVT is automatically dangerous, but rather that the finding is sufficiently “unusual” to require exclusion of underlying disease. The same logic extends clinically to recurrent couplets: the more the rhythm becomes “running” rather than isolated, the lower the threshold for further evaluation.

 

A couplet alone does not necessarily imply high absolute risk if the heart is otherwise normal, the finding is rare, monomorphic, not exercise-induced, and not accompanied by syncope or other warning features. In current thinking, a couplet is therefore often more of a feature favoring further evaluation than a marker of major absolute risk.

In the Scorza et al. / 2023 / PVC without structural heart disease prognosis study, patients with no prior heart disease and normal echocardiography and exercise testing did not have higher mortality than population controls during a median follow-up of 5.2 years.

 

In Hosseini et al. / 2022 / CMR in frequent PVCs, in the prospective cohort cited by the ACC, 13.7% of patients with frequent PVCs and “no known structural heart disease” had an abnormal CMR, and these abnormalities, together with NSVT, predicted worse outcomes.

​

Features favoring benignity

• no structural heart disease

• no syncope or exertional symptoms

• monomorphic PVC

• low PVC burden

• normal LV function

• ectopy decreases with exercise or does not increase

• morphology consistent with a typical idiopathic site of origin

• no family history of sudden cardiac death

 

Features favoring further evaluation

• structural heart disease or suspicion of it

• syncope, presyncope, exertional chest pain, or strong family history of sudden cardiac death

• polymorphic or multifocal morphology

• recurrent couplets, triplets, or NSVT

  • There is no single universal threshold for these per day; the decision depends more on overall assessment. Factors to consider include run length (3–4 beats vs >10 beats), rate (eg, 120–150/min vs about 200/min), recurrence (occasional vs several times daily/hourly), and short coupling / R-on-T features.

  • Examples of lower-concern findings include rare couplets and/or a single short NSVT run (eg, 3–5 beats), monomorphic morphology, no exercise-related increase, and no short coupling.

  • Findings that are more abnormal and more likely to justify further investigation include recurrent NSVT, long runs (roughly >10 beats), very fast runs (roughly >180–200/min), a polymorphic pattern, clear exercise provocation, or short-coupled PVCs.

 

Additional features favoring further evaluation include:

• high PVC burden

• unexplained impaired LV function

• increase in PVCs or increasing polymorphism during exercise or recovery

• abnormal resting ECG or CMR

• PVC-induced cardiomyopathy

​

​PVC-Induced Cardiomyopathy

A high PVC burden can cause or worsen left ventricular systolic dysfunction. In practice, risk begins to increase especially when PVC burden reaches about ≥10% of all daily beats and increases further as burden rises. A burden >20% is considered clearly more concerning. Levels >10,000–20,000 PVCs/day are also associated with an increased risk of cardiomyopathy.

 

Risk is further increased by:

• wide PVC QRS; the wider the QRS, the greater the myopathy risk

• long-standing high burden

• an unfavorable site of origin

• possible underlying myocardial disease

 

If the PVC burden is <10%, other causes of cardiomyopathy should also be actively sought.

Causality may be unclear: did a high PVC burden lead to dilatation, or is there an underlying dilated cardiomyopathy associated with PVCs? Resolution of a high PVC burden may also restore impaired LV function.

 

A high PVC burden can also reduce the percentage of effective biventricular pacing in CRT patients and thereby weaken treatment response.

 

Diagnostic Evaluation

Initial Evaluation

The cornerstones of evaluating a patient with PVCs are:

• careful history

• physical examination

• 12-lead ECG

 

The history should focus especially on:

• symptom type, frequency, and impact on quality of life

• provoking and worsening factors

• exercise relationship

• medications, stimulants, and drugs

• comorbid diseases

• family history, especially sudden death, cardiomyopathies, and inherited arrhythmia syndromes

 

Physical examination aims to identify signs of occult heart disease.

 

Basic laboratory tests are usually limited to:

• complete blood count

• electrolytes (Na, K, Mg, ionized Ca)

• thyroid tests

 

Chest radiography can be a useful additional study in selected cases.

​

ECG Diagnosis

The ECG diagnosis of a PVC is in principle straightforward. Typical features are:

• a premature wide QRS complex

• QRS duration >120 ms, often >140 ms

• no preceding P wave

• often a compensatory pause

• a possible retrograde P wave after the QRS

• usually QRS/ST-T discordance

 

As a rule, a premature wide QRS complex not clearly preceded by a visible P wave is considered ventricular in origin. This is not absolute, however, because an aberrantly conducted supraventricular beat can look very similar, and the P wave may be hidden within the preceding T wave.

 

A monomorphic PVC arises from the same focus. Polymorphic or multifocal ventricular ectopy suggests multiple sites of origin or a more unstable substrate.

 

Differential Diagnosis: How to Distinguish a PAC From a PVC

The most common differential diagnoses of a PVC are:

• aberrantly conducted premature atrial contraction (PAC)

• functional intermittent bundle branch block

• intermittent ventricular pacing

• intermittent WPW syndrome

• atrial flutter or atrial tachycardia with aberrant conduction

 

An aberrantly conducted PAC is most often seen with a right bundle branch block (RBBB) pattern, because the refractory period of the right bundle branch is usually longer than that of the left bundle. When a PAC occurs early, the impulse may reach the His–Purkinje system while the right bundle is still refractory but the left bundle has already recovered. The supraventricular impulse is then conducted to the ventricles aberrantly with an RBBB pattern.

 

An aberrantly conducted PAC may also resemble left bundle branch block or fascicular block. Features suggesting functional aberrancy include especially:

• variation in QRS width according to the prematurity of the ectopic beat

• an abnormal shape of the T wave preceding the ectopic beat when the P wave falls on the T wave

• absence of a compensatory pause

 

In PACs, the surface ECG P′ wave is not always clearly visible. It may be buried in the T wave (“P-on-T,” “camel hump”) or be visible only in some leads.

 

In the Ashman phenomenon, a long–short RR sequence favors aberrancy because a long RR interval prolongs the next refractory period of the His–Purkinje system, especially the bundle branches. When a short RR interval follows, the next supraventricular impulse may reach the conduction system before it has fully recovered. The impulse is then conducted aberrantly, most often with an RBBB pattern. The essence of Ashman phenomenon is that conduction system refractory time depends on the length of the preceding cycle: the longer the preceding RR interval, the longer the next refractory period.

 

Morphology and What It Can Suggest

In a structurally normal heart, idiopathic PVCs are often described as large-amplitude and mono- or biphasic in several leads (eg, R, QS, rS, qR). The T wave is often opposite in direction to the QRS. In practice, this means that an idiopathic PVC is often monomorphic and relatively “simple” in appearance, whereas scar- or cardiomyopathy-related PVCs may show more fragmentation, notching, and multiple phases.

 

A “high-voltage PVC,” however, is not a reliable benignity criterion. QRS amplitude depends on the lead, heart position, chest structure, distance to the electrodes, and site of origin. Likewise, a mono- or biphasic shape or ST-T discordance alone does not prove that the heart is healthy or that the PVC is benign.

 

An ECG lead records the projection of the net depolarization vector along its own axis. In a PVC, depolarization starts from a ventricular site and spreads via an abnormal route, so the mean QRS direction (axis) and morphology differ from normal conduction system activation. A PVC may therefore align “better” with a given lead and appear very large in that lead.

 

In structurally diseased hearts, QRS morphology can vary greatly depending on the type of myocardial disease. The complex is often lower in amplitude and more fragmented than in typical idiopathic outflow tract rhythms. On the other hand, an infarct scar-related re-entry arrhythmia may be completely monomorphic, and its morphology may correlate with the anatomical location of the scar.

 

Estimating PVC Site of Origin From the 12-Lead ECG

The 12-lead ECG often provides a good estimate of the anatomical area from which a PVC arises, especially in idiopathic outflow tract arrhythmias.

 

Basic principles:

• an RBBB-type morphology usually suggests a left ventricular origin

• an LBBB-type morphology usually suggests a right ventricular origin

 

In PVCs, activation does not begin in the normal conduction system but from an ectopic ventricular focus, so depolarization first spreads through the ventricle containing the focus and only then to the other ventricle. Thus, the surface ECG “bundle branch block” morphology essentially describes which ventricle is activated late. If the PVC arises in the left ventricle, activation initially travels from left to right, so the right ventricle is activated late and the QRS often resembles RBBB. If the PVC arises in the right ventricle, activation initially travels from right to left, so the left ventricle is activated late and the QRS often resembles LBBB.

​

Idiopathic RVOT ectopy typically has a QRS axis directed from superior to inferior and from right to left, resulting in an inferior axis, ie, leads II, III, and aVF are positive, and the morphology is LBBB-type.

​​

Precordial Transition

Precordial transition refers to the chest lead in which the QRS changes from predominantly negative to predominantly positive, ie, where R/S >1. In practice, it indicates the point where the net depolarization vector begins to point more toward the precordial leads than away from them.

​

In LBBB-pattern, inferior-axis outflow tract arrhythmias, transition is particularly useful:

• late transition, in V4 or later, more often supports an RVOT origin

• early transition, before V3, more often supports an LVOT / aortic cusp region origin

 

V3 is a gray zone in which the simple “before or after V3” rule works less well. More refined algorithms, such as the V2 transition ratio, are more useful in that setting.

 

In RBBB-pattern PVCs, transition can also be described, but it is not interpreted using the same simple RVOT–LVOT rule. In that setting, transition is more of an additional clue than a primary criterion.

 

A septal origin is usually narrower, “taller” in the inferior leads, and less fragmented than a free-wall origin. A negative QRS in lead I can, in a particular outflow tract context, suggest a more anterior or free-wall direction of origin, but this is not a general rule for all PVCs.

 

The 12-lead ECG localizes only the probable anatomical region or exit site, not the entire arrhythmic substrate. In structural heart disease, an “RVOT-looking” morphology alone does not prove that the arrhythmia is benign.

 

Ambulatory Monitoring

Holter monitoring or event ECG is an important adjunct when the aim is to:

• document the rhythm during symptoms

• assess PVC burden

• detect couplets, NSVT, or multiple morphologies

• evaluate treatment efficacy

• investigate paroxysmal tachycardia episodes

 

If symptoms clearly correspond to isolated ectopic beats and no high-risk features are present, long-term monitoring is not always necessary just to confirm the diagnosis of PVCs. If ectopy appears frequent or there is suspicion of another arrhythmia, ambulatory monitoring is usually justified.

 

A 24-hour Holter is not fully optimal for quantifying PVC burden, because the amount of ectopy may vary markedly from day to day. A patient may have a “good day” with, for example, 5,000 PVCs/day and a worse day with 15,000/day. Thus, a single recording does not always reflect the true long-term burden.

 

If Holter monitoring shows couplets, NSVT, or other complexity, it is often useful to:

• confirm morphology on a 12-lead ECG or a high-quality recording

• assess PVC burden, number of morphologies, and recurrence of runs

• consider whether the morphology fits an idiopathic or atypical site of origin

 

Echocardiography and CMR

Echocardiography is a key test when structural heart disease is suspected, PVC burden is high, or symptoms are significant.

 

Echocardiography assesses:

• wall motion and wall thickness

• valvular structure and function

• chamber sizes

• possible shunts

• pericardium

 

A normal echocardiogram is reassuring and strongly suggests benignity. On the other hand, a normal echocardiogram alone does not exclude small scars, early cardiomyopathy, or an inflammatory substrate. Thus, a normal echo is clinically reassuring but not an absolute exclusion.

​

CMR is readily indicated if any of the following are present:

• polymorphic or atypical PVCs

• recurrent couplets or NSVT

• unexplained reduced EF

• syncope

• abnormal resting ECG

• suspicion of ARVC, myocarditis, sarcoidosis, amyloidosis, or another infiltrative disease

 

If even early cardiomyopathy or ARVC is suspected, the patient should generally remain under specialist follow-up at least initially. Echocardiography can be repeated, for example, every 6–12 months; earlier if EF is borderline or declining, symptoms increase, or PVC burden rises. There is no exact guideline-defined interval. In a peer-reviewed expert review, asymptomatic patients with high PVC burden are recommended to undergo follow-up every 6–12 months to detect the development of heart failure.​​

​​​​

Why Cardiac MRI Is Performed in Patients With Frequent PVCs

Cardiac MRI is performed to look for the myocardial substrate from which they arise. In patients with frequent, atypical, polymorphic, or otherwise suspicious ventricular ectopy, the purpose of CMR is to detect occult structural heart disease that may remain invisible on routine ECG and even on echocardiography. Its particular strength is tissue characterization: it can identify scar, fibrosis, edema, fatty replacement, and other subtle myocardial abnormalities, while also providing accurate assessment of ventricular size and function. For this reason, current ESC guidance recommends considering CMR when the PVC/VT presentation is not typical of an idiopathic origin despite a normal echocardiogram, and also when PVC-induced cardiomyopathy is suspected. In a prospective cohort of patients with frequent PVCs and no known structural heart disease, CMR revealed myocardial abnormalities in 13.7%, and those abnormalities were associated with worse clinical outcomes.

 

In practice, CMR is used to look for conditions such as ischemic or non-ischemic scar, prior myocarditis, arrhythmogenic cardiomyopathy, and other cardiomyopathic processes that can provide a substrate for ventricular arrhythmia. It is also helpful when a high PVC burden raises concern that the ectopy itself may already be impairing left ventricular function.

 

Thus, the clinical question is usually not whether the patient “has PVCs”—that is already known—but whether there is concealed myocardial disease behind them, or whether the ectopy has begun to damage ventricular performance.

 

Polymorphic or Atypical PVCs Despite a Normal Resting ECG and Normal CMR

If the resting ECG is normal, CMR is normal, and obstructive coronary artery disease has been excluded, the differential diagnosis shifts away from overt structural heart disease and toward concealed electrical disease, subtle myocardial disease below the detection threshold of routine testing, or idiopathic ventricular ectopy arising from a non-classic site of origin. The most important single diagnosis to exclude in this setting is catecholaminergic polymorphic ventricular tachycardia (CPVT). CPVT classically presents with a structurally normal heart and a normal resting ECG, while exercise or emotional stress brings out ventricular ectopy that increases in complexity as heart rate rises, progressing from monomorphic PVCs to polymorphic PVCs and sometimes bidirectional or polymorphic VT. Other concealed primary electrical syndromes must also be considered, such as LQTS and concealed Brugada syndrome. Acquired and episodic causes should also be excluded, such as electrolyte disturbances and hyperthyroidism.

 

A normal resting ECG and normal CMR are reassuring findings because they make overt structural heart disease less likely, but they do not by themselves prove that polymorphic or morphologically atypical ventricular ectopy is benign. Multifocal PVCs and non-outflow tract left ventricular PVC origin have also been associated with a higher likelihood of finding myocardial abnormalities on CMR in patients initially thought to have no structural heart disease.

​​

Exercise Testing and Ischemia Assessment

Exercise testing is indicated if:

• symptoms occur during exertion

• there is exertional weakness or syncope

• ischemia is suspected

• the aim is to assess arrhythmia behavior during exertion

 

A decrease in ectopy during exercise is often reassuring, but it does not by itself exclude disease. Ventricular ectopy that increases with exercise, becomes more polymorphic, or increases during recovery warrants a lower threshold for further evaluation.

 

If exercise testing shows ischemic changes or the arrhythmia increases as workload increases, further coronary evaluation is indicated. As needed, this may proceed to coronary angiography or more detailed ischemia assessment.

 

Coupling Interval and Short-Coupled PVCs

The coupling interval of a PVC is the time from the onset of the preceding sinus QRS to the onset of the PVC.

• a fixed-coupling PVC occurs with nearly the same delay each time

• a variable-coupling PVC occurs at different delays on different occasions

 

Variable coupling may fit automaticity or parasystole. In parasystole, a ventricular focus discharges partly independently of sinus rhythm because it is protected from resetting by sinus impulses (entrance block), so PVCs do not appear at a constant coupling interval; rather, the interval varies. Parasystole may also be suggested by fusion beats and by interectopic intervals that fit multiples of the same basic cycle length. Variable coupling has been proposed as a possible clue to structural abnormality, but it does not by itself indicate danger. Conversely, a fixed-coupling PVC does not by itself indicate benignity, because monomorphic scar-related re-entry can also be highly fixed-coupled.

 

A short-coupled PVC occurs unusually early, often during the vulnerable phase of repolarization, the so-called R-on-T phenomenon. In practice, short coupling is often described as a coupling interval <300 ms. This is an uncommon but clinically important finding because it can predispose to polymorphic VT or ventricular fibrillation.

 

When Extensive Further Evaluation Is Often Not Needed

Extensive further evaluation (such as CMR, genetic testing, or invasive studies) is often unnecessary if all of the following are present:

• monomorphic pattern consistent with a typical idiopathic site of origin

• couplets or NSVT are rare/isolated

• no exercise provocation

• low PVC burden

• normal LV function

• no evidence of structural or electrical heart disease

• no syncope or other warning symptoms

 

In that setting, reassurance, follow-up, and if needed repeat Holter monitoring or echocardiography if symptoms or burden change are often sufficient.

 

Features that particularly support further investigation include:

• clearly polymorphic or multifocal PVCs

• recurrent NSVT or frequent couplets

• very short coupling interval or R-on-T tendency

• increase or increasing polymorphism during exercise

• morphology atypical for an idiopathic arrhythmia

• abnormal baseline ECG or concerning clinical risk profile

• arrhythmogenic syncope

• suspicion of a specific disease (eg, ARVC or cardiac sarcoidosis)

• family history of sudden death / unexplained death at young age

• unexplained reduced EF, especially if PVC burden is significant

• bundle branch block / conduction abnormality on ECG

 

In a patient with PVCs, even isolated RBBB may be a factor favoring further evaluation, although it does not by itself imply a dangerous arrhythmia. Its significance is that a conduction abnormality may suggest underlying cardiac or conduction system disease rather than a completely idiopathic PVC phenomenon, thereby lowering the threshold for further imaging (primarily echocardiography, and CMR if needed).

​

Treatment

General Principles

In a structurally normal heart, the main goal of treatment is symptom relief. In structural heart disease, treatment emphasis is on the underlying disease.

​

Lifestyle Measures and Sympathetic Tone

In symptomatic but benign ventricular ectopy, first-line management is:

• informing and reassuring the patient

• reducing caffeine, alcohol, and other stimulants that worsen symptoms

• smoking cessation

• correcting sleep deprivation, stress, depression-related sleep disturbance, and overexertion

• reviewing sympathomimetics and other medications that may worsen arrhythmia

• good treatment of underlying disease

 

Avoidance of caffeine has not been shown to benefit everyone, but if the patient recognizes a clear relationship to symptoms, avoidance is reasonable. Recovery from exhaustion, sleep deprivation, or overtraining often improves the situation within a few weeks.

 

Untreated hypertension can provoke PVCs, and treatment of hypertension may also reduce ectopic burden, partly through regression of LVH.

​

Beta Blockers

Beta blockers are first-line drug therapy for symptomatic, probably benign ventricular ectopy. They are safe and well suited to primary care. Their efficacy, however, is variable and often fairly modest.

​

Beta blockers work best when ectopy is related to sympathetic activation or occurs at higher heart rates. Short-acting propranolol can be used intermittently, for example 10–40 mg as needed, while once-daily preparations are usually used for longer-term treatment.

 

In some patients whose ectopy occurs mainly at slow heart rates, beta blockers may even increase PVCs. Thus, in ectopy that occurs during a slow resting heart rate, beta blockers may be proarrhythmic in some cases.

​

Their effect on PVC burden is usually modest, although symptoms may improve. In a randomized study, atenolol reduced both ectopy and symptoms in symptomatic idiopathic PVCs compared with placebo, but placebo improved symptoms almost as much. In patients with RVOT PVCs, carvedilol reduced mean PVC burden from 20.3% to 14.6% over 12 weeks. According to a recent review, a clinically meaningful reduction in PVCs is achieved with beta blockers in only about 12–24% of patients.

​

Verapamil or Diltiazem

If a beta blocker is contraindicated, poorly tolerated, or ineffective, verapamil or diltiazem can be considered, especially in selected idiopathic arrhythmias.

​

Flecainide and Propafenone

At the study level, there is evidence that flecainide may reduce burden more than a standard beta blocker in some idiopathic PVC populations. For example, in one comparative study flecainide reduced outflow tract PVC burden more than carvedilol, and in a retrospective series flecainide was more effective than propafenone or sotalol.

 

Use of flecainide or propafenone requires that structural heart disease be excluded.

 

In idiopathic PVCs, flecainide is clearly more effective than beta blockers. In a randomized carvedilol-versus-flecainide comparison, flecainide reduced PVC burden from 17.1% to 6.6% over 12 weeks, more than carvedilol. In a retrospective series, flecainide achieved >99% PVC reduction in 56% of patients and ≥80% reduction in 64%, which was better than with sotalol or propafenone.

​

Other Antiarrhythmic Drugs

Sotalol can sometimes be used selectively, but it is not first-line therapy for idiopathic PVCs, and there is no strong evidence that it is more effective than conventional beta blockers. In addition, it may excessively prolong the QT interval and cause proarrhythmic complications even in a structurally normal heart.

​

Amiodarone is used in relation to PVCs mainly in selected situations, not routinely: in practice, when the patient has structural heart disease or LV dysfunction, other options are unsuitable or ineffective, and suppression of arrhythmia burden is expected to provide clinical benefit. Class III drugs should not be used as first-line therapy in benign ventricular ectopy.

 

Amiodarone often suppresses PVCs effectively, but long-term toxicity limits its use. In the CHF-STAT trial, among patients with heart failure, LVEF ≤40%, and frequent ventricular ectopy, amiodarone reduced ventricular arrhythmias compared with placebo and improved LVEF, but did not improve overall survival in the entire study population.

​

The role of class IB drugs such as lidocaine and mexiletine in idiopathic PVCs in a healthy heart is limited, and their efficacy appears generally weaker than that of flecainide, for example.

​

Catheter Ablation

Catheter ablation is indicated, or at least strongly worth considering, when:

• symptoms are disabling

• medical therapy is ineffective or not tolerated

• there is frequent, monomorphic ectopy arising from a focus

• PVC burden is high and PVC-induced cardiomyopathy is suspected

• PVCs trigger ventricular tachycardia

 

Ablation results are especially good in idiopathic outflow tract and left fascicular arrhythmias. In a structurally normal but symptomatic patient, catheter ablation is an important treatment option, and according to the ESC it is first-line treatment in symptomatic RVOT or left fascicular PVC/VT arrhythmias.

​​

Pacing Therapy, Pulse Deficit, and Pseudobradycardia

Frequent very early PVCs can cause a pulse deficit and pseudobradycardia. If the ectopic beat occurs so early that the left ventricle does not have time to fill, the PVC may be hemodynamically nearly or completely ineffective. Thus, for example, bigeminy at 60/min may in practice correspond to a much slower effective perfusing rhythm.

​

In one physiological study, shortening the PVC coupling interval progressively reduced pulse pressure, and in some subjects the arterial pulse disappeared completely during the PVC.

 

Hemodynamic effect depends at least on:

• PVC prematurity

• PVC burden

• underlying heart rate

• cardiac structure and pump function

 

Not all PVCs are completely “wasted,” and some ectopic beats may be at least partly mechanically effective. The normal sinus beat following a PVC is also often stronger than usual because of post-extrasystolic potentiation.

​

If frequent PVCs coexist with slow sinus rhythm, low effective pulse rate, and symptoms, pacing therapy may selectively be considered, especially in structurally diseased hearts.

 

Structurally Normal Heart

Idiopathic Outflow Tract Ventricular Ectopy

The ESC emphasizes that idiopathic VT/PVC is a diagnosis of exclusion: if the presentation is not typical of an idiopathic rhythm, CMR should be considered despite normal echocardiography.

​

In addition, the RVOT, LVOT, aortic root cusps, and septal outflow regions are anatomically very close to each other. For this reason, a left-sided outflow or peri-aortic/septal exit can look very RVOT-like on ECG. For example, the right coronary cusp region lies immediately behind the septal RVOT, and their morphologies may be almost identical. In practice, therefore, an “RVOT-looking” morphology does not automatically mean that the ectopy is a benign idiopathic right ventricular PVC. In structural heart disease, the same localization rules are less reliable, and an LV infarct-scar arrhythmia can appear RVOT-like if its exit is near the outflow septum.

​

In a structurally normal heart, outflow tract PVCs or short VT bursts are usually monomorphic, morphologically typical of idiopathic rhythms, and most often benign. Symptoms may improve simply by knowing that the phenomenon is harmless and that normal daily life does not need to be restricted.

 

The prognosis of idiopathic RVOT ectopy is good when structural heart disease has been excluded by echocardiography (and MRI if needed), no VT has been documented, and LV systolic function is normal.

 

First-line medication is usually a beta blocker. If there is no subjective benefit, verapamil, diltiazem, or a class IC drug (flecainide, propafenone) may be considered. If ectopy is very frequent, >(10-)20% of all daily beats, cardiac structure and function should be monitored periodically by echocardiography because of the risk of PVC-induced cardiomyopathy. If follow-up shows a significant fall in EF, catheter ablation should be considered.

 

Some idiopathic PVCs resolve spontaneously over time.

 

Structurally Abnormal Heart

In structurally diseased hearts, the practical medication sequence for PVC suppression is usually beta blocker first, then amiodarone if needed, and selectively sotalol. In HCM, the current AHA/ACC guideline also names mexiletine and dofetilide for ventricular arrhythmias. In ARVC/ACM, the HRS consensus exceptionally also allows flecainide, but only together with a beta blocker, in an ICD patient with preserved LV/RV function. Flecainide and propafenone must not be used in patients with prior myocardial infarction or significant structural heart disease.

​

Coronary Artery Disease and Prior Myocardial Infarction

In patients with coronary artery disease, treatment should primarily optimize management of the underlying disease. A beta blocker is usually part of treatment. If the arrhythmia is related to myocardial ischemia, revascularization by PCI or CABG is the primary treatment.

​

A prior myocardial infarction may explain monomorphic ventricular arrhythmia present even at rest, with the mechanism often being scar-related re-entry.

​

Dilated Cardiomyopathy and Systolic Heart Failure

Frequent PVCs at rest may be the first sign of dilated cardiomyopathy. It is often characterized by ectopy occurring fairly continuously throughout the day, including at rest.

 

Treatment is directed primarily at optimal heart failure medication, including beta blockers. This does not necessarily eliminate the ectopy.

​

Hypertrophic Cardiomyopathy, Inflammatory and Infiltrative Cardiac Diseases

Hypertrophic cardiomyopathy, myocarditis, giant cell myocarditis, cardiac sarcoidosis, amyloidosis, hemochromatosis, and other infiltrative diseases may also present with ventricular arrhythmias.

​

Clues include, for example:

• conduction abnormalities on ECG

• abnormal echocardiogram

• reduced LV function

• atypical arrhythmia morphology

• abnormalities of wall structure or motion

 

CMR and, selectively, endomyocardial biopsy may be needed. Treatment is directed primarily at the underlying disease.

​

Valvular Disease

Ventricular ectopy is also common in valvular disease, especially mitral valve prolapse. Aortic stenosis and aortic regurgitation may likewise come to light in association with frequent ventricular ectopy.

 

Inherited Arrhythmia Syndromes

Although most ventricular arrhythmias in structurally normal hearts are benign, in rare cases ventricular ectopy may be a sign of an inherited arrhythmia syndrome. Genetic testing can be considered in specialist care based on clinical suspicion.

 

ARVC / ARVD

ARVC should be suspected when apparently RVOT-origin ectopy is present together with one or more of the following:

• ventricular tachycardia episodes

• syncope

• strong family history

• T-wave inversions in V1–V3

• QRS abnormalities in the right precordial leads

• epsilon wave

 

CMR is an important test in this setting. Treatment consists primarily of drug therapy, selectively catheter ablation, and ICD in high-risk situations. Competitive sports are avoided.

 

ARVC can be difficult to distinguish from benign idiopathic right ventricular ectopy, especially early in the disease, when structural RV abnormalities may not yet be visible on echocardiography. The disease should be suspected if, in addition to right outflow tract ventricular ectopy, there is ventricular tachycardia or impairment of consciousness, especially if the disease is known or strongly suspected in the family. ARVC is inherited in an autosomal dominant manner, but penetrance is incomplete.

​

CPVT

CPVT should be suspected if ventricular ectopy occurs only during exercise or increases clearly with exercise, especially if it is polymorphic or associated with presyncope or syncope. The resting ECG may be normal and the heart structurally normal. In some cases, the ectopy may also be monomorphic and occur during exercise, for example as bigeminy, without actual VT.

​

If the resting ECG is normal, the heart is structurally normal, and there is no evidence of coronary artery disease, exercise-induced polymorphic ventricular ectopy is highly suspicious for CPVT. Genetic testing can then be considered.

 

Treatment is permanent beta blocker therapy. If loss of consciousness occurs despite medical treatment, ICD therapy may need to be considered.

​

Long QT Syndrome

Long QT syndrome may present with isolated PVCs, polymorphic VT, or torsades de pointes. In type 2 long QT syndrome, arrhythmias may occur during or after exercise, but they may diminish during heavier exertion as the sinus rate rises. QTc is prolonged >470 ms. The T wave may be low-amplitude, bifid, or notched.

​

In type 7 long QT syndrome, ie, Andersen syndrome, ventricular ectopy may be associated with hypokalemic periodic paralysis. The underlying cause is a KCNJ2 mutation.

 

Treatment is with a beta blocker. If syncope occurs despite treatment, ICD evaluation is indicated.

 

“Triggers” for Additional Evaluation

(Even if echocardiography, ECG, and blood tests are normal)

• morphology atypical for an idiopathic arrhythmia

• clearly polymorphic / multifocal PVCs

• NSVT runs, especially recurrent

• increase with exercise or increasing polymorphism during exercise

• arrhythmogenic syncope or otherwise unexplained loss of consciousness / presyncope

• family history of unexplained sudden death at a young age

• suspicion of a specific underlying disease

• frequent couplets

• very short coupling interval / R-on-T tendency

 

The strongest message of the 2022 ESC guideline is that CMR should be considered if the PVC/VT presentation is not typical of an idiopathic origin despite normal echocardiography.

 

When to Refer to a Cardiologist / for Further Evaluation

Specialist assessment is indicated if any of the following are present:

• syncope or presyncope compatible with an arrhythmic cause

• paroxysmal tachycardia

• recurrent couplets, triplets, or NSVT

• polymorphic or multifocal PVCs

• short-coupled or R-on-T-type PVCs

• arrhythmia that increases during exercise

• suspected inherited arrhythmia syndrome or cardiomyopathy

• abnormal echocardiography or suspected need for CMR

• high PVC burden or suspected PVC-induced cardiomyopathy

• need to assess ablation, ICD, or other invasive treatment

 

In patients with syncope and palpitations, further evaluation is based on case-specific rhythm documentation. Initially this usually involves Holter monitoring, event recording, or if needed an implantable rhythm monitor.

 

Electrophysiologic study can also be considered when severe symptoms are absent but PVC burden is very high, morphology is fairly uniform, the arrhythmia appears to arise from a single focus, and symptoms are troublesome, allowing localization of the arrhythmia origin for possible catheter ablation.

 

Sports Restrictions

Ventricular ectopy in a healthy heart does not limit sports participation. This requires, however, that structural heart diseases (HCM, ARVC) have been excluded, the resting ECG is normal (normal QT interval, no delta wave, etc.), ventricular ectopy does not increase with exercise (CPVT), and there is no family history of sudden cardiac death of cardiac origin.

​